PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance
-
Published:2023-08-23
Issue:3
Volume:25
Page:441-450
-
ISSN:1535-1084
-
Container-title:NeuroMolecular Medicine
-
language:en
-
Short-container-title:Neuromol Med
Author:
Carlotto Bianca SoaresORCID, Trevisan PatriciaORCID, Provenzi Valentina OliveiraORCID, Soares Fabiano PasqualottoORCID, Rosa Rafael Fabiano MachadoORCID, Varella-Garcia MarileilaORCID, Zen Paulo Ricardo GazzolaORCID
Abstract
AbstractGlioblastoma (GBM) is the most frequent tumor of the central nervous system, and its heterogeneity is a challenge in treatment. This study examined tumoral heterogeneity involving PDGFRA, KIT, and KDR gene amplification (GA) in 4q12 and its association with clinical parameters. Specimens from 22 GBM cases with GA for the 4q12 amplicon detected by FISH were investigated for homogeneous or heterogeneous coamplification patterns, diffuse or focal distribution of cells harboring GA throughout tumor sections, and pattern of clustering of fluorescence signals. Sixteen cases had homogenously amplification for all three genes (45.5%), for PDGFRA and KDR (22.7%), or only for PDGFRA (4.6%); six cases had heterogeneous GA patterns, with subpopulations including GA for all three genes and for two genes - PDGFRA and KDR (13.6%), or GA for all three and for only one gene - PDGFRA (9.1%) or KIT (4.6%). In 6 tumors (27.3%), GA was observed in focal tumor areas, while in the remaining 16 tumors (72.7%) it was diffusely distributed throughout the pathological specimen. Amplification was universally expressed as double minutes and homogenously stained regions. Coamplification of all three genes PDGFRA, KIT, and KDR, age ≥ 60 years, and total tumor resection were statistically associated with poor prognosis. FISH proved effective for detailed interpretation of molecular heterogeneity. The study uncovered an even more diverse range of amplification patterns involving the 4q12 oncogenes in GBM than previously described, thus highlighting a complex tumoral heterogeneity to be considered when devising more effective therapies.
Funder
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brazil Conselho Nacional de Desenvolvimento Científico e Tecnológico
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology,Molecular Medicine
Reference41 articles.
1. Belsuzarri, T. A. B., Neves, M. W. F., Costa, O. A., Soares, D. A., Filho, F. A. M., Guimarães, M. M., Gonçales, T. F., Zeviani, W. M., & Araújo, J. F. M. (2018). Heterogeneidade dos tumores cerebrais. Brazilian Neurosurgery. https://doi.org/10.1055/s-0038-1625962 2. Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E. B., Suki, D., Sawaya, R., & Glantz, M. (2016). Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncology, 2(11), 1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373 3. Burford, A., Little, S. E., Jury, A., Popov, S., Laxton, R., Doey, L., Al-Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2013). Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma. PLoS ONE, 8(8), e71777. https://doi.org/10.1371/journal.pone.0071777 4. Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013). The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 501(7467), 338–345. https://doi.org/10.1038/nature12625 5. Cantanhede, I. G., & de Oliveira, J. R. M. (2017). PDGF family expression in glioblastoma multiforme: Data compilation from ivy glioblastoma atlas project database. Scientific Reports, 7(1), 15271. https://doi.org/10.1038/s41598-017-15045-w
|
|